Mutations associated with occult hepatitis B virus infection result in decreased surface antigen expression in vitro

Journal of Viral Hepatitis

Volumn 19, Issue 10, 2012, Pages 716-723

  Martin, C M ^a   Welge, J A ^a   Rouster, S D ^a   Shata, M T ^a   Sherman, K E ^a   Blackard, J T ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

G145A; HBV HIV co infection; hepatitis B surface antigen; hepatitis B surface antigen mutants; occult hepatitis B virus

Indexed keywords

HEPATITIS B SURFACE ANTIGEN;

ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; CELL LYSATE; CONTROLLED STUDY; EXPRESSION VECTOR; GENE MUTATION; GENETIC TRANSFECTION; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; SUPERNATANT; WILD TYPE;

CELL LINE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATOCYTES; HUMANS; MUTAGENESIS, SITE-DIRECTED; MUTATION, MISSENSE;

EID: 84866242067     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2012.01595.x     Document Type: Article

References (48)

1. Lavanchy D,. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11 (2): 97-107.
2. Lok ASF, McMahon BJ,. Chronic hepatitis B. Hepatology 2007; 45 (2): 507-539.
3. Bodsworth NJ, Cooper DA, Donovan B,. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis 1991; 163 (5): 1138-1140.
4. Jilg W, Sieger E, Zachoval R, Schatzl H,. Individuals with antibodies against hepatitis B core antigen as the only serological marker for hepatitis B infection: high percentage of carriers of hepatitis B and C virus. J Hepatol 1995; 23 (1): 14-20.
5. Shire NJ, Rouster SD, Stanford SD, et al., The prevalence and significance of occult hepatitis B virus in a prospective cohort of HIV-infected patients. J Acquir Immune Defic Syndr 2007; 44 (3): 309-314.
6. Lok AS, Everhart JE, Di Bisceglie AM, et al., Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology 2011; 54 (2): 434-442.
7. Ikeda K, Kobayashi M, Someya T, et al., Occult hepatitis B virus infection increases hepatocellular carcinogenesis by eight times in patients with non-B, non-C liver cirrhosis: a cohort study. J Viral Hepat 2009; 16 (6): 437-443.
8. Kannangai R, Molmenti E, Arrazola L, et al., Occult hepatitis B viral DNA in liver carcinomas from a region with a low prevalence of chronic hepatitis B infection. J Viral Hepat 2004; 11 (4): 297-301.
9. Matsuoka S, Nirei K, Tamura A, et al., Influence of occult hepatitis B virus coinfection on the incidence of fibrosis and hepatocellular carcinoma in chronic hepatitis C. Intervirology 2008; 51 (5): 352-361.
10. Squadrito G, Pollicino T, Cacciola I, et al., Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients. Cancer 2006; 106 (6): 1326-1330.
11. Tamori A, Nishiguchi S, Kubo S, et al., Sequencing of human-viral DNA junctions in hepatocellular carcinoma from patients with HCV and occult HBV infection. J Med Virol 2003; 69 (4): 475-481.
12. Baginski I, Chemin I, Hantz O, et al., Transmission of serologically silent hepatitis B virus along with hepatitis C virus in two cases of posttransfusion hepatitis. Transfusion 1992; 32 (3): 215-220.
13. Campe H, Hillebrand GF, Mairhofer H, Nitschko H, Jager G,. Undetected chronic hepatitis B virus infection of a vaccinated dialysis patient after liver transplantation. Nephrology, Dialysis, Transplantation 2005; 20 (7): 1492-1494.
14. Thiers V, Nakajima E, Kremsdorf D, et al., Transmission of hepatitis B from hepatitis-B-seronegative subjects. Lancet 1988; 2 (8623): 1273-1276.
15. Yuen M-F, Ka-Ho Wong D, Lee C-K, et al., Transmissibility of hepatitis B virus (HBV) infection through blood transfusion from blood donors with occult HBV infection. Clin Infect Dis 2011; 52 (5): 624-632.
16. Hofer M, Joller-Jemelka HI, Grob PJ, Luthy R, Opravil M,. Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Swiss HIV Cohort Study. Eur J Clin Microbiol Infect Dis 1998; 17 (1): 6-13.
17. Nunez M, Rios P, Perez-Olmeda M, Soriano V,. Lack of 'occult' hepatitis B virus infection in HIV-infected patients. AIDS 2002; 16 (15): 2099-2101.
18. Rodríguez-Torres M, Gonzalez-Garcia J, Bräu N, et al., Occult hepatitis B virus infection in the setting of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection: clinically relevant or a diagnostic problem? J Med Virol 2007; 79 (6): 694-700.
19. Torbenson M, Kannangai R, Astemborski J, Strathdee SA, Vlahov D, Thomas DL,. High prevalence of occult hepatitis B in Baltimore injection drug users. Hepatology 2004; 39 (1): 51-57.
20. Hu K-Q,. Occult hepatitis B virus infection and its clinical implications. J Viral Hepat 2002; 9 (4): 243-257.
21. Martin CM, Welge JA, Shire NJ, et al., Genomic variability associated with the presence of occult hepatitis B virus in HIV co-infected individuals. J Viral Hepat 2010; 17 (8): 588-597.
22. Weinberger KM, Bauer T, Bohm S, Jilg W,. High genetic variability of the group-specific a-determinant of hepatitis B virus surface antigen (HBsAg) and the corresponding fragment of the viral polymerase in chronic virus carriers lacking detectable HBsAg in serum. J Gen Virol 2000; 81 (5): 1165-1174.
23. Kao J-H, Chen P-J, Lai M-Y, Chen D-S,. Sequence analysis of pre-S/surface and pre-core/core promoter genes of hepatitis B virus in chronic hepatitis C patients with occult HBV infection. J Med Virol 2002; 68 (2): 216-220.
24. Chu C-J, Keeffe EB, Han S-H, et al., Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology 2003; 125 (2): 444-451.
25. Günther S, Li BC, Miska S, Kruger DH, Meisel H, Will H,. A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J Virol 1995; 69 (9): 5437-5444.
26. Hass M, Hannoun C, Kalinina T, Sommer G, Manegold C, Günther S,. Functional analysis of hepatitis B virus reactivating in hepatitis B surface antigen-negative individuals. Hepatology 2005; 42 (1): 93-103.
27. Jeantet D, Chemin I, Mandrand B, Zoulim F, Trepo C, Kay A,. Characterization of two hepatitis B virus populations isolated from a hepatitis B surface antigen-negative patient. Hepatology 2002; 35 (5): 1215-1224.
28. Schories M, Peters T, Rasenack J,. Isolation, characterization and biological significance of hepatitis B virus mutants from serum of a patient with immunologically negative HBV infection. J Hepatol 2000; 33 (5): 799-811.
29. Amini-Bavil-Olyaee S, Alavian S-M, Adeli A, et al., Hepatitis B virus genotyping, core promoter, and precore/core mutations among Afghan patients infected with hepatitis B: a preliminary report. J Med Virol 2006; 78 (3): 358-64.
30. Bock CT, Tillmann HL, Torresi J, et al., Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 2002; 122 (2): 264-273.
31. Echevarría JM, Avellõn A,. Hepatitis B virus genetic diversity. J Med Virol 2006; 78 (S1): S36-S42.
32. Seddigh-Tonekaboni S, Waters JA, Jeffers S, et al., Effect of variation in the common "a" determinant on the antigenicity of hepatitis B surface antigen. J Med Virol 2000; 60 (2): 113-121.
33. El Chaar M, Candotti D, Crowther RA, Allain JP,. Impact of hepatitis B virus surface protein mutations on the diagnosis of occult hepatitis B virus infection. Hepatology 2010; 52 (5): 1600-1610.
34. Jeantet D, Chemin I, Mandrand B, et al., Cloning and expression of surface antigens from occult chronic hepatitis B virus infections and their recognition by commercial detection assays. J Med Virol 2004; 73 (4): 508-515.
35. Louisirirotchanakul S, Khupulsup K, Akraekthalin S, et al., Comparison of the technical and clinical performance of the Elecsys HBsAg II assay with the Architect, AxSym, and Advia Centaur HBsAg screening assays. J Med Virol 2010; 82 (5): 755-762.
36. Mizuochi T, Okada Y, Umemori K, Mizusawa S, Yamaguchi K,. Evaluation of 10 commercial diagnostic kits for in vitro expressed hepatitis B virus (HBV) surface antigens encoded by HBV of genotypes A to H. J Virologic Meth 2006; 136 (1-2): 254-256.
37. Moerman B, Moons V, Sommer H, Schmitt Y, Stetter M,. Evaluation of sensitivity for wild type and mutant forms of hepatitis B surface antigen by four commercial HBsAg assays. Clin Lab 2004; 50 (3-4): 159-162.
38. Coleman PF, Chen YC, Mushahwar IK,. Immunoassay detection of hepatitis B surface antigen mutants. J Med Virol 1999; 59 (1): 19-24.
39. Wu C, Zhang X, Tian Y, et al., Biological significance of amino acid substitutions in hepatitis B surface antigen (HBsAg) for glycosylation, secretion, antigenicity and immunogenicity of HBsAg and hepatitis B virus replication. J Gen Virol 2010; 91 (2): 483-492.
40. Bruss V, Ganem D,. Mutational analysis of hepatitis B surface antigen particle assembly and secretion. J Virol 1991; 65 (7): 3813-3820.
41. Kalinina T, Riu A, Fischer L, Will H, Sterneck M,. A dominant hepatitis B virus population defective in virus secretion because of several S-gene mutations from a patient with fulminant hepatitis. Hepatology 2001; 34 (2): 385-394.
42. Khan N, Guarnieri M, Ahn SH, et al., Modulation of hepatitis B virus secretion by naturally occurring mutations in the S gene. J Virol 2004; 78 (7): 3262-3270.
43. Blum HE, Galun E, Liang TJ, von Weizsacker F, Wands JR,. Naturally occurring missense mutation in the polymerase gene terminating hepatitis B virus replication. J Virol 1991; 65 (4): 1836-1842.
44. Blum HE, Liang TJ, Galun E, Wands JR,. Persistence of hepatitis B viral DNA after serological recovery from hepatitis B virus infection. Hepatology 1991; 14 (1): 56-63.
45. Miyagawa M, Minami M, Fujii K, et al., Molecular characterization of a variant virus that caused de novo hepatitis B without elevation of hepatitis B surface antigen after chemotherapy with rituximab. J Med Virol 2008; 80 (12): 2069-2078.
46. Sengupta S, Rehman S, Durgapal H, Acharya SK, Panda SK,. Role of surface promoter mutations in hepatitis B surface antigen production and secretion in occult hepatitis B virus infection. J Med Virol 2007; 79 (3): 220-228.
47. Mello FC, Martel N, Gomes SA, Araujo NM,. Expression of hepatitis B virus surface antigen containing Y100C variant frequently detected in occult HBV infection. Hepat Res Treat 2011; 695859.
48. Ito K, Qin Y, Guarnieri M, et al., Impairment of hepatitis B virus virion secretion by single-amino-acid substitutions in the small envelope protein and rescue by a novel glycosylation site. J Virol 2010; 84 (24): 12850-12861.